Daxor Announces Blood Volume Research Receives Top Citation Honors at 2006 Society of Critical Care Medicine Symposium.

NEW YORK -- Daxor Corporation (AMEX:DXR), a medical instrumentation and biotechnology company, today announced Top Citation Honors for clinical outcome research data presented at the 35th Critical Care Congress - 2006 Society of Critical Care Medicine Symposium (SCCM), which was held this month in San Francisco, CA.

Each year the SCCM accepts clinical abstracts concerning research being conducted within the critical care arena. Out of 600 clinical abstracts which were submitted for consideration, five are awarded Top Citation Honors. Dr. Elisabeth Biuk-Aghai from the Department of Surgery, Division of Surgical Critical Care, Queens Medical Center, University of Hawaii, Honolulu, HI, was awarded Top Citation Honors for her research, "Blood Volume Measurements: Impact on Fluid Management".

Dr. Biuk-Aghai, along with Dr. Hideko Yamauchi, Dr. Mihae Yu, Dr. Hao Chih Ho, Dr. Alyssa Chapital and Dr. Danny Takanishi, reported that the utilization of Daxor's Blood Volume Analyzer BVA-100 to guide fluid management therapy of 40 patients that were studied within the Intensive Care Unit at Queens Medical Center resulted in a positive clinical response in 42% of the cases.

"Our research demonstrated that by altering our treatment based on blood volume measurement, patients experienced improved kidney function, cardiac index and blood oxygenation levels," noted Dr. Biuk-Aghai. Dr. Mihae Yu, Professor of Surgery at the University of Hawaii stated that, "Correct fluid management in critically ill patients is essential, and the measurement of blood volume provided a change in our fluid management 45% of the time compared to existing methods like pulmonary artery catheter measurements."

"The result of this data demonstrates that Daxor's BVA-100 provides improved patient care in the intensive critical care unit," stated John Reyes-Guerra, Daxor's V.P. of Sales & Marketing. "Thousands of patients every day require critical fluid management therapies in the ICU. Prior to the BVA-100, physicians have had to make clinical judgments based upon various methods, none of which measure a patient's blood volume status. The BVA-100 eliminates the guess work. All of the preliminary research, like the work being done at Queens Medical Center, continues to show that blood volume analysis could become a standard of care in the critical care unit."

Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with a single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website www.Daxor.com, or contact Stephen Feldschuh, 212-330-8515 (VP of Operations) [e-mail] or Diane Meegan, 212-330-8512 (Investor Relations) [e-mail].